ICON PLC reports quarterly earnings Monday as investors seek their first clear look at the clinical research giant’s operations since it completed a months-long accounting investigation.
Analysts expect the Dublin-based contract research organization to post adjusted earnings of $3.00 per share on revenue of $1.96 billion, marking sequential declines.
ICON remains the world’s second-largest clinical research organization. Analysts rate the stock a Buy, with a mean price target of $132.60.
Investors are watching whether ICON will reinstate guidance and provide restated financials.
